ArdelyxARDX
ARDX
About: Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Employees: 267
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
39% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 33
19% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 62
5% more funds holding
Funds holding: 201 [Q3] → 211 (+10) [Q4]
3.39% more ownership
Funds ownership: 60.36% [Q3] → 63.75% (+3.39%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
22% less capital invested
Capital invested by funds: $979M [Q3] → $766M (-$213M) [Q4]
23% less call options, than puts
Call options by funds: $14.5M | Put options by funds: $18.9M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5.50
1%
upside
Avg. target
$10.08
86%
upside
High target
$15
177%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
Scotiabank Louise Chen 37% 1-year accuracy 52 / 142 met price target | 177%upside $15 | Sector Outperform Initiated | 7 Mar 2025 |
Ladenburg Thalmann Aydin Huseynov 30% 1-year accuracy 3 / 10 met price target | 103%upside $11 | Buy Assumed | 7 Mar 2025 |
Raymond James Ryan Deschner 44% 1-year accuracy 4 / 9 met price target | 140%upside $13 | Strong Buy Reiterated | 21 Feb 2025 |
HC Wainwright & Co. Ed Arce 39% 1-year accuracy 62 / 159 met price target | 1%upside $5.50 | Neutral Reiterated | 21 Feb 2025 |
Piper Sandler Christopher Raymond 30% 1-year accuracy 9 / 30 met price target | 48%upside $8 | Neutral Maintained | 27 Jan 2025 |
Financial journalist opinion
Based on 13 articles about ARDX published over the past 30 days
Neutral
GlobeNewsWire
5 hours ago
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy
Neutral
Seeking Alpha
1 week ago
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, providing investment ideas and sparking discussions on their potential. Edtech company Udemy is seen as on the rise and is a Strong Buy from Weebler Finance. Jumia Technologies shows resilience and growth potential in African e-commerce, despite market skepticism and low stock prices.
Neutral
GlobeNewsWire
2 weeks ago
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval
Neutral
GlobeNewsWire
2 weeks ago
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2025 Global Healthcare Conference Location: Miami, FLPresentation: Tuesday, March 11 at 8:00 a.m.
Negative
Seeking Alpha
2 weeks ago
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments.
Positive
Seeking Alpha
2 weeks ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Neutral
Seeking Alpha
2 weeks ago
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
Call End: Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2024 Earnings Conference Call February 20, 2025 8:00 A.M. ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & CEO Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz – Citigroup Dennis Ding – Jefferies Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Julian Harrison – BTIG Ryan Deschner - Raymond James Thomas Yip - H.C.
Positive
The Motley Fool
2 weeks ago
Ardelyx Tops Estimates as Sales Surge
Ardelyx (ARDX -8.10%), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release highlighted considerable progress in the company's commercialization of its two approved drugs, Ibsrela and Xphozah.
Positive
Zacks Investment Research
3 weeks ago
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
3 weeks ago
Ardelyx (ARDX) Meets Q4 Earnings Estimates
Ardelyx (ARDX) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Charts implemented using Lightweight Charts™